The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Study ID: NCT04665856
Brief Summary: The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Beijing Cancer Hospital, Beijing, , China
Beijing Chest Hospital; Oncology Department, Beijing, , China
the First Affiliated Hospital of Bengbu Medical College, Bengbu City, , China
the First Hospital of Jilin University, Changchun, , China
Fujian Provincial Cancer Hospital, Fuzhou City, , China
Cancer Center of Guangzhou Medical University, Guangzhou, , China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, , China
Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department, Hangzhou City, , China
Harbin Medical University Cancer Hospital, Harbin, , China
The 1st Affiliated Hospital of Nanchang Unversity, Nanchang, , China
Fudan University Shanghai Cancer Center, Shanghai City, , China
Shanghai Chest Hospital, Shanghai, , China
Zhongshan Hospital Fudan University, Shanghai, , China
Cancer Hospital of Shantou University Medical College, Shantou, , China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, , China
Henan Cancer Hospital, Zhengzhou, , China
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR